JACOBS LEVY EQUITY MANAGEMENT, INC

Position in DSGN — Design Therapeutics, Inc.

CIK 884414 FLORHAM PARK, NJ

Position in DSGN

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$3,079,056

+$1,253,605 QoQ

Shares Held

289,385

+48.7% QoQ

Ownership

0.463%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

10 quarters on record

Voting authority Sole 87% Shared 0% None 13%

Healthcare · as of Mar 31, 2026

JACOBS LEVY EQUITY MANAGEMENT, INC holds $706,432,200 across 86 Biotechnology names. DSGN ranks #29 (0.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	214,160	$165,468,582
2	INCY	Incyte Corp	1,717,978	$161,696,089
3	ALNY	Alnylam Pharmaceuticals, Inc.	212,204	$70,211,937
4	HALO	Halozyme Therapeutics, Inc.	789,429	$51,020,796
5	RARE	Ultragenyx Pharmaceutical Inc.	1,431,071	$29,980,937
6	EXEL	Exelixis, Inc.	425,982	$18,270,367
7	AUPH	Aurinia Pharmaceuticals Inc.	1,097,189	$16,260,340
8	ARVN	Arvinas, Inc.	1,441,521	$15,280,122

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$3,079,056	289,385	+48.7%	Shares	Sole	2026-05-15
2025-12-31	$1,825,451	194,611	+1341.5%	Shares	Sole	2026-02-13
2025-06-30	$45,498	13,501	-22.8%	Shares	Sole	2025-08-14
2025-03-31	$67,480	17,482	-4.3%	Shares	Sole	2025-05-15
2024-12-31	$112,670	18,261	-93.5%	Shares	Sole	2025-02-14
2024-09-30	$1,507,857	280,271	-41.2%	Shares	Sole	2024-11-14
2024-06-30	$1,595,464	476,258	-5.1%	Shares	Sole	2024-08-14
2024-03-31	$2,023,140	502,020	-8.6%	Shares	Sole	2024-05-15
2023-12-31	$1,455,162	549,118	+3310.7%	Shares	Sole	2024-02-14
2023-06-30	$101,430	16,100	—	Shares	Sole	2023-08-14
No filing history on record for this holder in this stock.